Rockwell Medical, Inc. (NASDAQ:RMTI) Short Interest Update

Rockwell Medical, Inc. (NASDAQ:RMTI) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,120,000 shares, an increase of 25.3% from the October 31st total of 893,900 shares. Approximately 4.0% of the company’s stock are short sold. Based on an average daily trading volume, of 797,600 shares, the short-interest ratio is presently 1.4 days.

Institutional Trading of Rockwell Medical

Several large investors have recently made changes to their positions in RMTI. Concurrent Investment Advisors LLC purchased a new stake in shares of Rockwell Medical in the 3rd quarter valued at $40,000. Verus Capital Partners LLC purchased a new stake in shares of Rockwell Medical in the 3rd quarter valued at $51,000. Barclays PLC purchased a new stake in shares of Rockwell Medical in the 3rd quarter valued at $90,000. Beacon Financial Advisory LLC purchased a new stake in shares of Rockwell Medical in the 3rd quarter valued at $98,000. Finally, XTX Topco Ltd boosted its holdings in shares of Rockwell Medical by 45.7% in the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock valued at $113,000 after acquiring an additional 8,922 shares during the last quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Stock Up 3.2 %

NASDAQ:RMTI opened at $2.29 on Monday. The company has a market cap of $74.01 million, a PE ratio of -45.80 and a beta of 1.50. Rockwell Medical has a twelve month low of $1.16 and a twelve month high of $5.15. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average is $3.35 and its two-hundred day moving average is $2.67.

Wall Street Analyst Weigh In

RMTI has been the topic of a number of analyst reports. StockNews.com downgraded shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. HC Wainwright dropped their target price on shares of Rockwell Medical from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, November 25th. Finally, Rodman & Renshaw assumed coverage on shares of Rockwell Medical in a research report on Thursday, November 14th. They set a “buy” rating and a $5.00 target price on the stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.